Regulus Therapeutics Inc.

$8.16+0.00%(+$0.00)
TickerSpark Score
62/100
Mixed
47
Valuation
20
Profitability
60
Growth
84
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGLS research report →

52-Week Range98% of range
Low $0.83
Current $8.16
High $8.35

Companywww.regulusrx.com

Regulus Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

CEO
Joseph P. Hagan
IPO
2012
Employees
34
HQ
San Diego, CA, US

Price Chart

+281.31% · this period
$8.30$4.64$0.97Jun 25Dec 23Jun 26

Valuation

Market Cap
$564.95M
P/E
-24.08
P/S
1661.62
P/B
7.82
EV/EBITDA
-23.26
Div Yield
0.00%

Profitability

Gross Margin
-50.59%
Op Margin
-7142.35%
Net Margin
-6595.59%
ROE
-30.84%
ROIC
-34.48%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-46,358,000 · -54.34%
EPS
$-0.82 · 48.10%
Op Income
$-50,040,000
FCF YoY
-53.44%

Performance & Tape

52W High
$8.35
52W Low
$0.83
50D MA
$7.14
200D MA
$2.89
Beta
0.37
Avg Volume
2.16M

Get TickerSpark's AI analysis on RGLS

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jun 25, 25RASTETTER WILLIAM Hother44,264
Jun 25, 25RASTETTER WILLIAM Hsell30,000
Jun 25, 25RASTETTER WILLIAM Hsell15,000
Jun 25, 25RASTETTER WILLIAM Hsell60,000
Jun 25, 25RASTETTER WILLIAM Hsell2,325
Jun 25, 25RASTETTER WILLIAM Hsell9,000
Jun 25, 25RASTETTER WILLIAM Hsell4,000
Jun 25, 25RASTETTER WILLIAM Hsell57,292
Jun 25, 25RASTETTER WILLIAM Hsell4,650
Jun 25, 25Witz Pascalesell4,000

Our RGLS Coverage

We haven't published any research on RGLS yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate RGLS Report →

Similar Companies